KRYS Stock Overview
A commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Krystal Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$178.10 |
| 52 Week High | US$219.34 |
| 52 Week Low | US$99.00 |
| Beta | 0.82 |
| 11 Month Change | -0.49% |
| 3 Month Change | -9.83% |
| 1 Year Change | 74.57% |
| 33 Year Change | 319.65% |
| 5 Year Change | 207.12% |
| Change since IPO | 1,573.87% |
Recent News & Updates
Krystal Biotech, Inc. (NASDAQ:KRYS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Nov 07
Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
Oct 14Recent updates
Krystal Biotech, Inc. (NASDAQ:KRYS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Nov 07Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
Oct 14Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)
Jul 31Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think
May 13Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch
Feb 28Krystal Biotech: Ready For Launch
Feb 20We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth
Jan 02Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth
Sep 06Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?
Aug 08We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
May 17We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Jan 30Krystal Biotech cleared to file EU marketing application for rare skin disease therapy
Sep 22We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
Aug 30Krystal Biotech: Solid Performance, Let's Keep Holding
Aug 18Krystal Biotech GAAP EPS of -$1.10 misses by $0.07
Aug 08Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis
Aug 01Krystal Biotech: High Potential, Buy-At-Dips Stock
May 25We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Apr 20Krystal Biotech: The Future Looks More And More Derisked
Feb 21Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications
Nov 30Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout
Sep 27Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation
Sep 25Shareholder Returns
| KRYS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.3% | -6.5% | -1.0% |
| 1Y | 74.6% | 14.6% | 30.3% |
Return vs Industry: KRYS exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: KRYS exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| KRYS volatility | |
|---|---|
| KRYS Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KRYS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KRYS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 229 | Krish Krishnan | www.krystalbio.com |
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.
Krystal Biotech, Inc. Fundamentals Summary
| KRYS fundamental statistics | |
|---|---|
| Market cap | US$5.12b |
| Earnings (TTM) | US$52.37m |
| Revenue (TTM) | US$241.52m |
97.8x
P/E Ratio21.2x
P/S RatioIs KRYS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KRYS income statement (TTM) | |
|---|---|
| Revenue | US$241.52m |
| Cost of Revenue | US$17.98m |
| Gross Profit | US$223.54m |
| Other Expenses | US$171.16m |
| Earnings | US$52.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.82 |
| Gross Margin | 92.55% |
| Net Profit Margin | 21.68% |
| Debt/Equity Ratio | 0% |
How did KRYS perform over the long term?
See historical performance and comparison